Assuntos
Adenocarcinoma/sangue , Carcinoma de Células Escamosas/sangue , Neoplasias do Colo do Útero/sangue , Fator de von Willebrand/análise , Adulto , Idoso , Antígenos/análise , Fator VIII/análise , Feminino , Fibrinogênio/análise , Humanos , Pessoa de Meia-Idade , Neoplasias do Colo do Útero/patologia , Neoplasias do Colo do Útero/cirurgiaRESUMO
The Authors measured Factor VIII Related Antigen (FVIIIR:Ag), Factor VIII Coagulant Activity (FVIII:C) and fibrinogen plasma levels in 21 patients with cervical carcinoma and in 14 ones with ovarian carcinoma. In the women with cervical cancer, FVIIIR:Ag was significantly higher than controls only in advanced stages. No significant variation of fibrinogen according to stage and no correlation between FVIIIR:Ag and fibrinogen plasma levels were observed. In the patients with ovarian cancer FVIIIR:Ag was significantly increased in stage III-IV and not significantly in stage I. In these subjects too there was a lack of correlation between FVIIIR:Ag and fibrinogen plasma levels. These results seem to indicate that FVIIIR:Ag increase in advanced stages is due to its major release in circulation resulting from invasion of vascular endothelium and not to an aspecific reactivity. These data could suggest a role of FVIIIR:Ag as an aspecific marker of vascular involvement by cervical and ovarian neoplasms.
Assuntos
Antígenos/metabolismo , Fator VIII/imunologia , Neoplasias Ovarianas/sangue , Neoplasias do Colo do Útero/sangue , Adulto , Idoso , Fator VIII/metabolismo , Feminino , Fibrinogênio/metabolismo , Humanos , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Células Neoplásicas Circulantes , Neoplasias Ovarianas/patologia , Prognóstico , Neoplasias do Colo do Útero/patologia , Fator de von WillebrandAssuntos
Arterite de Células Gigantes/imunologia , Isoantígenos/análise , Polimialgia Reumática/imunologia , Fator de von Willebrand/imunologia , Idoso , Idoso de 80 Anos ou mais , Feminino , Seguimentos , Arterite de Células Gigantes/tratamento farmacológico , Glucocorticoides/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Polimialgia Reumática/tratamento farmacológicoRESUMO
A comprehensive study of haemostasis has been performed in a homogeneous group of 25 adult patients with conservatively treated chronic uraemia. We have found prolonged bleeding time, impaired platelet adhesiveness and aggregation, and decreased platelet factor 3 activity, increased values of fibrinogen, of factor VIII activity and related antigen, and of combined levels of factors II, VII and X. Non-significantly abnormal concentrations of factor XIII and of plasminogen and significantly lower values of plasminogen activators and higher values of urokinase inhibitors and anti-plasmin have also been found. Fibrinogen degradation products were detected in the urine of some patients.
Assuntos
Fatores de Coagulação Sanguínea/análise , Hemostasia , Uremia/sangue , Adulto , Doença Crônica , Fator VIII/análise , Produtos de Degradação da Fibrina e do Fibrinogênio/urina , Fibrinogênio/metabolismo , Fibrinólise , Hemorragia , Humanos , Plasminogênio/metabolismo , Adesividade Plaquetária , Fator Plaquetário 3/análise , Ativador de Plasminogênio Tipo Uroquinase/antagonistas & inibidoresRESUMO
A comprehensive study of haemostasis has been performed in a homogeneous group of 20 patients with nephrotic syndrome without renal failure. We have found unchanged number of platelets and a significant increase of platelet adhesiveness and aggregation; increased levels of activity and related antigen of fibrinogen, of factor VIII, of activity of factors II, VII and X and of antigens of factors XIII. Antithrombin III was unchanged in plasma and was detected in the urine. Euglobulin lysis times were decreased, and levels of plasminogen and its activators were increased after a venous occlusion test. At the same time urokinase inhibitors and antiplasmins were increased not only after, but also before a venous occlusion test. Fibrinogen degradation products have been found in the urine of all our patients but not in their sera.
Assuntos
Hemostasia , Síndrome Nefrótica/sangue , Trombose/etiologia , Adulto , Antitrombina III/análise , Fator VIII/análise , Produtos de Degradação da Fibrina e do Fibrinogênio/análise , Fibrinogênio/análise , Humanos , Síndrome Nefrótica/complicações , Adesividade Plaquetária , Albumina Sérica/análiseRESUMO
Factor IX activity (IX:C) and antigern (IX:Ag) as well as factor VII, prothrombin time, Normotest and Thrombotest were determined in 37 haemophiliacs B from 26 kindreds, in 30 carriers of haemophilia B and in 40 healthy subjects. In 15 obligatory carriers from 9 kindreds, in which haemophiliacs did not exhibit IX:Ag in excess of IX:C, IX:C was parallel with IX:Ag, but in 4 from 4 kindreds, in which haemophiliacs exhibit excess of IX:Ag, there was a discrepancy between IX:C and IX:Ag. Among the obligatory carriers 6 from 3 kindreds, in which haemophiliacs did not have IX:Ag in excess of IX:C, showed that the anomaly M is not a sign of genetic variability of haemophilia B.
Assuntos
Epitopos , Fator IX/imunologia , Triagem de Portadores Genéticos/métodos , Variação Genética , Hemofilia B/genética , Fator IX/fisiologia , Feminino , Hemofilia B/imunologia , Humanos , Imunoeletroforese , Masculino , Tempo de Tromboplastina ParcialRESUMO
Antithrombin III (At-III) activity and protein, heparin cofactor activity, antifactor Xa activity were determined in 200 healthy adults, evenly distributed within age and sex groups, in 60 patients with cerebral thrombosis and in 20 oral contraceptive users. There was a positive correlation between At-III protein and its activities in normal subjects and in patients with cerebral thrombosis. The mean At-III protein and heparin cofactor activity values decreased with age in men and in women of fertile age. The mean values of At-III protein and its activities did not show any variation in the patients with cerebral thrombosis when compared with the normals. In oral contraceptive users a positive correlation was also found between At-III protein and its activities, antifactor Xa activity excepted. The mean antifactor Xa activity value in these women decreased during treatment, whereas the other At-III activities and At-III protein were unchanged.